Note 13 - Segment Information

12 Months Ended

Jun. 30, 2024

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 13. Segment Information

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The Company has divided its operations into two reportable segments; Contract Manufacturing and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe, for the fiscal years ended June 30, 2024 and 2023 were $7,973 and $8,055, respectively.

Financial information relating to the fiscal years ended June 30, 2024 and 2023 operations by business segment are as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital		Total
		Customers		Customers		Total		Profit		Depreciation		Expenditures		Assets
Contract Manufacturing	2024	$	40,622	$	7,946	$	48,568	$	3,702	$	317	$	550	$	20,830
	2023		40,230		8,047		48,277		3,630		348		109		19,507
Other Nutraceutical Businesses	2024		1,722		27		1,749		182		2		3		5,377
	2023		2,387		8		2,395		431		3		7		5,924
Total Company	2024		42,344		7,973		50,317		3,884		319		553		26,207
	2023		42,617		8,055		50,672		4,061		351		116		25,431